Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

Neuro-Oncology

Volumn 13, Issue 4, 2011, Pages 401-409

  Ellingson, Benjamin M ^a   Cloughesy, Timothy F ^a   Lai, Albert ^a   Nghiemphu, Phioanh L ^a   Mischel, Paul S ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Glioblastoma; MRI; Volumetric analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; LOMUSTINE;

ARTICLE; CANCER SIZE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; VOLUMETRY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955759814     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq206     Document Type: Article

References (28)

1. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol. 1994;4(3) 207-218. (Pubitemid 24261926)
2. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994-1998. (Pubitemid 29309448)
3. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects Trends Mol Med. 2007;13(6):223-230. (Pubitemid 46836870)
4. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217-1222.
5. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(1253-9).
6. Friedman AH, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvent temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
8. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
9. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology. 2008;70(10):779-787.
10. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466-2474.
11. Earnest F, 4th, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166(3):823-827. (Pubitemid 18058950)
12. Kelly PJ, Daumas-Duport C, Kispert DB, Kail BA, Scheithauer BW, Illig JJ. maging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865-874. (Pubitemid 17085708)
13. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histological correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc. 1987;62(6):450-459. (Pubitemid 17084816)
14. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34(6):463-469.
15. Brant-Zawadski M, Norman D, Newton TH. Magnetic resonance imaging of the brain: the optimal screening technique. Radiology. 1984;152:71-77. (Pubitemid 14083156)
16. Byrne TN. Imaging of gliomas. Semin Oncol. 1994;21:162-171 (Pubitemid 24125956)
17. Husstedt HW, Sickert M, Köstler H, Haubitz B, Becker H. Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol. 2000;10(5):745-752. (Pubitemid 30321084)
18. Tsuchiya K, Mizutani Y, Hachiya J. Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors. AJNR Am J Neuroradiol. 1996;17(6):1081-1086. (Pubitemid 26198514)
19. Essig M, Hawighorst H, Schoenberg SO, et al. Fast fluid-attenuated Inversion-recovery (FLAIR) MRI in the assessment of intraaxial brain tumors. J Magn Reson Imaging. 1998;8(4):789-798. (Pubitemid 28357585)
20. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200-1206.
21. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91 (3)329-335.
22. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11) 1963-1972.
23. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5) 740-745.
24. Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab Magn Reson Med. 2010;63(5):1366-1375.
25. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
26. Ellingson BM, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2010. Published online ahead of print August 27, 2010.
27. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-4721 (Pubitemid 350086472)
28. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology. 2010;255(2) 622-628.